In colorectal cancers, the epigenetic regulator CBX3 has been shown to inhibit IFN-γ signaling through its binding to the promoters of STAT1 and PD-L1, thereby modulating the chronic inflammatory response-mediated tumorigenesis and mitigating therapeutic resistance (173). Here, IFNG is linked to colorectal cancer.